Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
14.12
+0.38 (2.77%)
Feb 24, 2025, 12:14 PM EST - Market open
Aardvark Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 4.44 | 2.17 | 2.7 |
| Research & Development | 10.84 | 4.48 | 7.17 |
| Operating Expenses | 15.57 | 7.42 | 10.36 |
| Operating Income | -15.57 | -7.42 | -10.36 |
| Interest & Investment Income | 1.82 | 1.42 | 0.12 |
| EBT Excluding Unusual Items | -13.75 | -5.99 | -10.24 |
| Gain (Loss) on Sale of Investments | -0.1 | -1.22 | -2.32 |
| Asset Writedown | - | - | -1 |
| Pretax Income | -13.85 | -7.21 | -13.56 |
| Net Income | -13.85 | -7.21 | -13.56 |
| Net Income to Common | -13.85 | -7.21 | -13.56 |
| Shares Outstanding (Basic) | 4 | 4 | 4 |
| Shares Outstanding (Diluted) | 4 | 4 | 4 |
| Shares Change (YoY) | 2.06% | 1.78% | - |
| EPS (Basic) | -3.49 | -1.82 | -3.49 |
| EPS (Diluted) | -3.49 | -1.82 | -3.49 |
| Free Cash Flow | -11.62 | -5.82 | -10.54 |
| Free Cash Flow Per Share | -2.93 | -1.47 | -2.71 |
| EBIT | -15.57 | -7.42 | -10.36 |
Source: S&P Capital IQ. Standard template.
Financial Sources.